Kamau Therapeutics

Engineering the cell’s own repair pathway

Kamau directs homology-directed repair to make precise therapeutic changes in long-lived blood stem cells. We control the process from editing through manufacturing to create medicines designed for lasting benefit from a single intervention.

HBB TARGET

Our approach

Process control supports reproducible precision

Kamau integrates editing, cell processing, analytics, and manufacturing to direct homology-directed repair at chosen genomic sites and make it reproducible at clinical scale.

Direct precise repair

A targeted editing system and donor template guide sequence correction at a chosen genomic site.

Preserve stemness

Process conditions are designed to support cell viability, self-renewal, engraftment potential, and multilineage function.

Define the product

Cells are characterized for identity, precision, potency, quality, and safety before administration.

Learn with every cycle

Each development and manufacturing cycle expands the evidence connecting process, product, and clinical outcomes. Those insights strengthen process control and inform the programs that follow.

Therapeutic reach

One stem cell
Multiple therapeutic paths

HSCs sit upstream of red blood cells and diverse immune cell lineages throughout the body. Engineering this common cellular source creates the potential to carry therapeutic change through the progeny it continually produces.

Correct a native sequence

Aim to restore healthy function 

Correcting a disease-causing sequence at its native genomic locus preserves the gene’s natural regulation. nula-cel applies this approach to the HBB locus in sickle cell disease, with the goal of restoring production of adult hemoglobin.

Discover Nula-cel

Program a new function

Equip immune cells for therapeutic action

Inserting a therapeutic sequence at a selected genomic site can give HSC-derived immune cells a programmed function. Kamau is applying this capability to new approaches in oncology.

Deliver a therapeutic protein

Create a potentially lasting source within the CNS

HSC-derived cells can populate the central nervous system and create the potential for localized delivery of therapeutic proteins. Kamau is exploring this approach across neurological diseases.

View our pipeline

Manufacturing and access

Engineering the treatment model

Kamau is developing closed, automated manufacturing systems designed for consistency, throughput, and efficiency. As these systems advance, they can expand capacity and support broader patient access.